Apalutamide Does Not Impact Patient-Reported Side Effect Burden, HRQOL in mCSPC
May 2nd 2022The addition of apalutamide to androgen deprivation therapy does not lead to a significant patient-reported side effect burden nor a reduction in health-related quality of life in patients with metastatic castration-sensitive prostate cancer.
Nurse Takeaways: 2022 ASCO Genitourinary Cancers Symposium at a Glance
April 21st 2022PARP inhibitors emerge as frontline treatment in metastatic castration-resistant prostate cancer, immunotherapy combinations improve quality of life in advanced renal cell carcinoma, and antibody drug conjugates show promise in cisplatin-ineligible urothelial cancer.
FDA Approves 177Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
March 24th 2022Lutetium-177-PSMA-617 is now FDA-approved for the treatment of patients with metastatic castration-resistant prostate cancer who have already received androgen receptor pathway inhibition and taxane-based chemotherapy.
5-Year Follow-Up Confirms Health-Related QOL Benefit With Nivolumab/Ipilimumab in Advanced RCC
February 25th 2022The immunotherapy combination of nivolumab and ipilimumab elicited favorable health-related quality of life responses compared with sunitinib in patients with advanced renal cell carcinoma.
Olaparib Is Linked With Decreased Pain Burden in Metastatic Castration-Resistant Prostate Cancer
February 25th 2022Compared with enzalutamide or abiraterone acetate tablets, olaparib was associated with decreased pain burden and better health-related quality of life in patients with castration-resistant prostate cancer.
Niraparib/Abiraterone Combo Linked to Improved rPFS in Select Patients With mCRPC
February 18th 2022A frontline regimen of niraparib, abiraterone acetate, and prednisone yielded improved radiographic progression-free survival in patients with homologous recombination repair gene altered–metastatic castration-resistant prostate cancer.
Women Who Receive Organ-Sparing Robotic Cystectomy Experience Preserved Sexual, Urinary Function
December 7th 2021A retrospective study presented at the 22nd SUO Annual Meeting revealed that pelvic organ–preserving robot-assisted radical cystectomy allowed women to return to sexual activity post-surgery.
18F-fluciclovine PET/CT Significantly Influences ADT Plans for Patients with Prostate Cancer
December 6th 2021A secondary analysis of 2 treatment alterations studies demonstrated that 18F-fluciclovine PET/CT scans play a pivotal role in determining if androgen deprivation therapy is appropriate for patients with prostate cancer.